A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase.

Trial Profile

A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2013

At a glance

  • Drugs Pitolisant (Primary)
  • Indications Hypersomnia
  • Focus Therapeutic Use
  • Acronyms HARPS 2
  • Most Recent Events

    • 08 Feb 2013 Planned end date changed from 1 Sep 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 08 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Aug 2012 Additional trial locations (Czech Republic and Sweden) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top